From Yahoo Finance: 2025-05-29 00:19:00

AbbVie Inc. (NYSE: ABBV) showcased advancements in its oncology pipeline at ASCO 2025, revealing positive clinical data for next-gen ADCs Temab-A and ABBV-706. Temab-A achieved a 63% response rate in pre-treated NSCLC patients, while ABBV-706 delivered a 61% response rate in second-line SCLC, outperforming existing therapies.

Despite these milestones, ABBV’s stock price remained stable at $187.15. Analysts predict an 11% upside with a consensus price target of $210.68, reflecting confidence in ABBV’s long-term performance and revenue potential as its pipeline evolves.

While ABBV shows promise, some believe other AI stocks offer greater potential returns with limited downside risk. For those seeking a promising AI stock with significant upside, a report highlights the potential of a specific AI stock for massive gains.

AbbVie Inc. highlighted major advancements in its oncology pipeline at the ASCO 2025 Annual Meeting, unveiling promising clinical data for its next-generation antibody-drug conjugates (ADCs), Temab-A and ABBV-706. Temab-A achieved a 63% objective response rate in pre-treated EGFR-mutated non-small cell lung cancer (NSCLC) patients.

Read more: AbbVie Inc. (ABBV)’s Pipeline Advances with Temab-A and ABBV-706, Shares Flat